EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas

Craig Erker iD, Magimairajan Issai Vanan iD, Valérie Larouche iD, Liana Nobre, Chantel Cacciotti, Stéphanie Vairy iD, Shayna Zelcer, Adam Fleming iD, Eric Bouffet iD, Nada Jabado iD, Geneviève Legault, Samuele Renzi und 16 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31070299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Craig Erker und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Dalhousie University, Halifax, NS B3H 4R2, Canada. Hauptthemen laut MEDLINE: Glioma, Mutation, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of BRAF V600E gliomas with BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been increasingly integrated into clinical practice for pediatric low-grade gliomas (PLGGs) and pediatric high-grade gliomas (HGGs). However, some questions remain unanswered, such as the best time to start targeted therapy, duration of treatment, and discontinuation of therapy. Given that no clinical trial has been able to address these critical questions, we developed a Canadian Consensus statement for the treatment of BRAF V600E mutated pediatric as well as adolescent and young adult (AYA) gliomas.

Methods

Canadian neuro-oncologists were invited to participate in the development of this consensus. The consensus was discussed during monthly web-based national meetings, and the algorithms were revised until a consensus was achieved.

Results

A total of 26 participants were involved in the development of the algorithms. Two treatment algorithms are proposed, one for the initiation of treatment and one for the discontinuation of treatment. We suggest that most patients with BRAF V600E gliomas should be treated with BRAFis ± MEKis upfront. Discontinuation of treatment can be considered in certain circumstances, and we suggest a slow wean.

Conclusions

Based on expert consensus in Canada, we developed algorithms for treatment initiation of children and AYA with BRAF V600E gliomas as well as a discontinuation algorithm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaMutationProto-Oncogene Proteins B-rafAdolescentChildFemaleHumansMaleYoung AdultBrain NeoplasmsCanadaProtein Kinase Inhibitors

Stichwörter der Autor:innen

BRAF V600E mutationBRAF inhibitorMEK inhibitorgliomahigh-grade gliomapediatric low-grade glioma

Substanzen

BRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Pediatrics, Dalhousie University, Halifax, NS B3H 4R2, Canada.
  • Division of Pediatric Hematology-Oncology, IWK Health Centre, Halifax, NS B3K 6R8, Canada.
  • Pediatric Neuro-Oncology, Division of Pediatric Hematology-Oncology and BMT, Cancer Care Manitoba, 3a Department of Pediatrics and Child Health, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T…
  • Department of Pediatric Hemato-Oncology, CHU de Québec-Université Laval, Quebec City, QC G1V 4G2, Canada.
  • Department of Pediatrics, University of Alberta, Edmonton, AB T6G 2R3, Canada.
  • Division of Hematology/Oncology, Department of Pediatrics, London Health Sciences Centre & Western University, London, ON N6A 5A5, Canada.

ORCID-Profile: Craig Erker, Magimairajan Issai Vanan, Valérie Larouche, Stéphanie Vairy, Adam Fleming, Eric Bouffet, Nada Jabado, Bruce Crooks, Vijay Ramaswamy, Seth Andrew Climans

Zitieren

APA

Erker, C., Vanan, M. I., Larouche, V., Nobre, L., Cacciotti, C., Vairy, S., Zelcer, S., Fleming, A., Bouffet, E., Jabado, N., Legault, G., Renzi, S., McKeown, T., Crooks, B., Thacker, N., Ramaswamy, V., Coltin, H., Lafay-Cousin, L., Cheng, S., …, & Perreault, S. (2024). Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas. Current Oncology. https://doi.org/10.3390/curroncol31070299

Vancouver

Erker C, Vanan MI, Larouche V, Nobre L, Cacciotti C, Vairy S, et al. Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas. Current Oncology. 2024. doi:10.3390/curroncol31070299

BibTeX
@article{Erker2024,
  author = {Erker, Craig and Vanan, Magimairajan Issai and Larouche, Valérie and Nobre, Liana and Cacciotti, Chantel and Vairy, Stéphanie and Zelcer, Shayna and Fleming, Adam and Bouffet, Eric and Jabado, Nada and Legault, Geneviève and Renzi, Samuele and McKeown, Tara and Crooks, Bruce and Thacker, Nirav and Ramaswamy, Vijay and Coltin, Hallie and Lafay-Cousin, Lucie and Cheng, Sylvia and Hukin, Juliette and Climans, Seth Andrew and Lim-Fat, Mary Jane and McKillop, Sarah and Lapointe, Sarah and Alves, Mélanie and Bennett, Julie and Tabori, Uri and Perreault, Sébastien},
  title = {Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31070299}
}
Kostenlos starten →